Premarin is is a mixture of estrogen hormones used to treat menopause symptoms such as hot flashes, vaginal dryness, irritation and dryness, to prevent osteoporosis in postmenopausal women.
Pharmacological groups of Premarin
Estrogens, progestins; antagonists, and their homologs
Antineoplastic hormonal and hormone antagonists
The nosological classification (ICD-10) of Premarin
C61 Malignant neoplasm of prostate
E28 Ovarian dysfunction
M81.0 postmenopausal osteoporosis
N91 lack of menstruation, scanty and rare menstruation
N93 Other abnormal bleeding from the uterus and vagina
Unspecified N94.6 Dysmenorrhea
N95.1 menopausal and menopausal status of women
Structure and Composition of Premarin
1 tablet contains 0.625 mg of conjugated estrogens; in box 1 blister 28 pcs.
Premarin 0.625 mg
Pharmacodynamics of Premarin
It relieves or eliminates the climacteric syndrome (sensation of heat, sweating, dizziness, irritability, depression), prevents the development of osteoporosis, prevents involution of the genitals, and normalizes the menstrual cycle in women of childbearing age, reduces the level of testosterone in men.
Indications for use of Premarin
Climacteric syndrome, estrogen deficiency in menopausal and postmenopausal, postmenopausal osteoporosis, dysfunctional uterine bleeding, dysmenorrhea, amenorrhea, cancer of the prostate.
Contraindications of Premarin
Breast cancer and estrogen-dependent tumors; uterine bleeding of unknown etiology; thrombophlebitis, violation of blood coagulation, thromboembolic disease; severe diseases of the cardiovascular system; expressed human liver or kidney; sickle cell anemia; congenital hearing loss; prolonged immobilization.
Hypersensitivity, pregnancy, estrogen-dependent malignancies or suspicion on them, unusual or undiagnosed genital or uterine bleeding, thrombophlebitis or thromboembolic disease in active phase (excluding treatment of breast and prostate cancer).
Thrombophlebitis, thrombosis or thromboembolism (while taking estrogens in history); family hyperlipoproteinemia, pancreatitis, endometriosis, gallbladder disease in history (especially cholelithiasis), severe liver failure, jaundice (including history during previous pregnancy), hepatic porphyria, leiomyoma, hypercalcemia associated with bone metastases from breast cancer .
Only for treatment of breast and prostate cancer: diseases of the coronary or cerebral vessels, active thrombophlebitis or thromboembolic disease (high-dose estrogens, used for the treatment, increase the risk of myocardial infarction, thromboembolism, pulmonary vessels, thrombophlebitis).